


Human Intelligence Enhanced by Artificial Intelligence

A REVOLUTION IN CARDIOVASCULAR IDENTIFICATION AND MANAGEMENT


CardioCare

Digital Health Platform

The CardioCare platform identifies at-risk patients with heart failure and a reduced ejection fraction who could benefit from guideline-directed medical therapy.



FEW HF_rEF PATIENTS OBSERVED ON 3+ GDMT CLASSES DESPITE KNOWN BENEFITS¹



1. Analysis from egnite's database of sites participating in the CardioCare platform representing 20 heart programs (both teaching and non-teaching included) managing a total of 97,874 patients with HF_rEF as of December 1, 2022. Here, GDMT includes an ACEi/ARB/ARNi, beta blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor per the 2022 AHA/ACC/HFSA guidelines for heart failure.

guideline-directed medical therapy (GDMT), heart failure with reduced ejection fraction (HF_rEF)

DELIVERING ON-DEMAND INSIGHTS OF YOUR HFrEF PATIENT POPULATION TO REDUCE VARIABILITY IN CARE & HELP ENSURE GDMT



The CardioCare platform provides insights to help you improve survival and reduce hospitalizations for your heart failure patients.



Automatically identify HFrEF patients who are not receiving full GDMT.



Guide facility- and MD-level outreach for patient evaluation and follow-up.



Ensure eligible HFrEF patients with multiple hospitalizations receive appropriate GDMT.

For more information, please visit egnitehealth.com/solutions

[@egnitehealth](https://twitter.com/egnitehealth) | [in linkedin.com/company/egnite-health/](https://www.linkedin.com/company/egnite-health/)

The CardioCare platform is not intended for use in the diagnosis, cure, mitigation, or prevention of cardiovascular diseases.

©2023 egnite, Inc. All Rights Reserved. egnite, egnite Inc., the spark logo, CardioCare, and the heart logo are trademarks of egnite, Inc or its affiliates. All other trademarks are property of their respective owners.

PP-US-058 v2.0

